About TAGCyx
TAGCyx is a company based in Yokohama (Japan) founded in 2007. TAGCyx has raised $4.9 million across 2 funding rounds from investors including SBI Group, UTokyo Innovation Platform and Healthcare Innovation. TAGCyx operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and UCB, among others.
- Headquarter Yokohama, Japan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.9 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
SBI Group
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of TAGCyx
Unlock access to complete
Unlock access to complete
Funding Insights of TAGCyx
TAGCyx has successfully raised a total of $4.9M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TAGCyx
TAGCyx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include SBI Group, UTokyo Innovation Platform and Healthcare Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Accelerator and venture capital services are provided by UTokyo-backed platform.
|
Locked | Locked | Locked | |
|
Investment fund focused on biotech and healthcare ventures in Japan.
|
Locked | Locked | Locked | |
|
Seed and Early stage VC firm investing in Japan
|
Locked | Locked | Locked |
Investor details for TAGCyx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TAGCyx
Investment portfolio details for TAGCyx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TAGCyx
Detailed financials for TAGCyx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tagcyx Comparisons
Peer comparison for TAGCyx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TAGCyx
TAGCyx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and UCB, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of TAGCyx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tagcyx
Complete news archive for TAGCyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TAGCyx
TAGCyx was founded in 2007 and raised its 1st funding round 9 years after it was founded.
TAGCyx is headquartered in Yokohama, Japan. It is registered at Yokohama, Kanagawa, Japan.
TAGCyx is a funded company, having raised a total of $4.9M across 2 funding rounds to date.
TAGCyx was founded in 2007 in Yokohama, Japan, as a biotechnology firm focused on nucleic acid therapeutics. A platform called Xenoligo is utilized to screen extensive libraries of oligonucleotides incorporating non-natural bases, through a modified SELEX process involving selection and PCR amplification cycles. A pipeline of drug candidates has been developed targeting autoimmune diseases, hematology, and nephrology indications. Operations center on advancing these candidates toward clinical applications.
TAGCyx's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
TAGCyx has 6 investors. Key investors include SBI Group, UTokyo Innovation Platform, Healthcare Innovation, UT-EC Japan, and Nissay Capital.